Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects.

Frontiers in immunology - 1 Jan 2023

Cheng Daoan, Ge Kele, Yao Xue, Wang Banglu, Chen Rui, Zhao Weiqing, Fang Cheng, Ji Mei

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line standard treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. However, resistance to EGFR-TKIs is inevitable. Currently, most studies on the mechanism of EGFR-TKIs resistance mainly focus on the spontaneous resistance phenotype of NSCLC cells. Studies have shown that the tumor microenvironment (TME)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Tumor-Associated Macrophages

Share to Tumor Microenvironment

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 37649478
DOI: 10.3389/fimmu.2023.1209947
PMCID: PMC10463184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects.PMID 37649478Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Tumor immune microenvironment in non-small cell lung cancer with EGFR mutation before and after EGFR-TKIs treatmentSemantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity Read ↗

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read ↗

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance.Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.